- Trials with a EudraCT protocol (613)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
613 result(s) found for: Active Rheumatoid Arthritis AND Arthritis.
Displaying page 31 of 31.
EudraCT Number: 2008-007346-63 | Sponsor Protocol Number: ALS-003-2008 | Start Date*: 2011-04-05 |
Sponsor Name:Alloksys Life Sciences B.V. | ||
Full Title: Reumap: An Open Label phase II study of Bovine Intestinal Alkaline Phosphatase (bIAP), An Inflammation modulating moiety, in RA patients | ||
Medical condition: Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003146-41 | Sponsor Protocol Number: 50021031-2 | Start Date*: 2007-03-08 | |||||||||||
Sponsor Name:Charité-Universitätsmedizin Berlin; Department of Rheumatology and Clinical Immunology | |||||||||||||
Full Title: A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHO... | |||||||||||||
Medical condition: Musculoskeletal disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000255-13 | Sponsor Protocol Number: 11-019 | Start Date*: 2012-06-20 | |||||||||||
Sponsor Name:Portola Pharmaceuticals, Inc. | |||||||||||||
Full Title: Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Me... | |||||||||||||
Medical condition: Prophylaxis of venous thromboembolism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) LV (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) LT (Completed) AT (Completed) DK (Completed) CZ (Completed) BG (Completed) IT (Completed) FI (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001836-44 | Sponsor Protocol Number: UCL/11/0119 | Start Date*: 2012-06-11 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: A Phase II Trial to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients with Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | |||||||||||||
Medical condition: Patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001027-20 | Sponsor Protocol Number: CACZ885GDE01T | Start Date*: 2012-04-03 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension. | |||||||||||||
Medical condition: adult onset Still's disease (AOSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000256-33 | Sponsor Protocol Number: Ra-P-OCD-01 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:Uppsala University Hospital | |||||||||||||
Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement | |||||||||||||
Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005268-41 | Sponsor Protocol Number: HE5A/15 | Start Date*: 2016-04-25 | |||||||||||
Sponsor Name:Hellenic Cooperative Oncology Group | |||||||||||||
Full Title: Phase ΙΙ (window) preoperative study of olaparib with or without cisplatin or no treatment in patients with histologically proven squamous cell carcinoma of the head and neck who are candidates for... | |||||||||||||
Medical condition: Histologically proven operable squamous cell carcinoma of the head and neck. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000044-25 | Sponsor Protocol Number: 1143-201 | Start Date*: 2013-07-16 | |||||||||||
Sponsor Name:Debiopharm S.A. | |||||||||||||
Full Title: A Phase I/II randomized study to determine the maximum tolerated dose, safety, pharmacokinetics and antitumor activity of Debio1143 combined with concurrent Chemo-Radiation Therapy in patients with... | |||||||||||||
Medical condition: Patients with locally advanced squamous cell carcinoma of the head and neck | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000541-41 | Sponsor Protocol Number: N/A | Start Date*: 2021-04-22 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial | |||||||||||||
Medical condition: SARS-CoV-2- infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005137-42 | Sponsor Protocol Number: Debio1143-EOC-203 | Start Date*: 2016-04-29 | |||||||||||
Sponsor Name:Debiopharm International SA | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Neoadjuvant Carboplatin and Paclitaxel, With or Without Debio 1143 in Patients With Newly Diagnosed Advanced Epithelial Ovarian Cancer. | |||||||||||||
Medical condition: Newly Diagnosed Advanced Epithelial Ovarian Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020004-30 | Sponsor Protocol Number: A3921080 | Start Date*: 2010-10-05 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 AND 1 SUBCUTANEOUS DOSE OF ETANERCEPT IN SUBJECTS ... | |||||||||||||
Medical condition: Moderate to Severe Chronic Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) CZ (Completed) ES (Completed) HU (Completed) NL (Completed) SK (Completed) BG (Completed) AT (Completed) PT (Completed) BE (Completed) DK (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000720-17 | Sponsor Protocol Number: MOM-M281-006 | Start Date*: 2020-01-14 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study with a Long-term Open-label Extension | |||||||||||||
Medical condition: Adults with Warm Autoimmune Hemolytic Anemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Temporarily Halted) HU (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001984-31 | Sponsor Protocol Number: A3921030 | Start Date*: 2007-08-08 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017 | |||||||||||||
Full Title: A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NO... | |||||||||||||
Medical condition: Prevention of kidney allograft rejection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PT (Completed) ES (Completed) NL (Completed) CZ (Completed) BE (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
